Kenichi Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kenichi Tanaka has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
Yosuke Okada
First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan
9 shared publications- Yoshiya Tanaka
Department of Molecular Targeted Therapeutics, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
6 shared publications - Akira Kurozumi
Department of Rheumatology and Diabetes, Wakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu 808-0024, Japan
3 shared publications Hidenori Yoshii
Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine Tokyo Japan
3 shared publicationsIichiro Shimomura
Department of Metabolic Medicine Osaka University Graduate School of Medicine Osaka Japan
3 shared publicationsKeiichi Torimoto
First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, uoeh-u.ac.jp
3 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (10) , 1794-1806
Association of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients
Background: The glycation gap (GGap), defined as the discrepancy between glycated hemoglobin (HbA1c) and the value estimated from actual blood glucose level, is associated with diabetic complications, but its association with hypoglycemia remains unclear. Methods: We evaluated the association between GGap and continuous glucose monitoring (CGM)‐based hypoglycemic indices in patients with type 2 diabetes mellitus (T2DM). Baseline data from a multicenter cohort of 999 T2DM patients without cardiovascular disease were analyzed. The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap, and various CGM indices were compared among low (≤0.16), medium (0.60) GGap tertile groups. Results: In the high GGap group, the average blood glucose was lower, while the Time Below Range ) and ), and low blood glucose index (LBGI) were higher than in the low and middle GGap groups. Patients with minimum blood glucose levels of ≥ 4%, and TBR ≥ 1% had significantly higher GGap values. Conclusion: This is the first study to show the strong association of high GGap with CGM‐based hypoglycemic indices in T2DM. To achieve diabetes treatment that effectively prevents the progression of diabetic complications, it is essential to assess the GGap of the individual patient before intensifying diabetes management.
- 29 July 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (10) , 1794-1806
Open AccessAssociation of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients
Background: The glycation gap (GGap), defined as the discrepancy between glycated hemoglobin (HbA1c) and the value estimated from actual blood glucose level, is associated with diabetic complications, but its association with hypoglycemia remains unclear. Methods: We evaluated the association between GGap and continuous glucose monitoring (CGM)‐based hypoglycemic indices in patients with type 2 diabetes mellitus (T2DM). Baseline data from a multicenter cohort of 999 T2DM patients without cardiovascular disease were analyzed. The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap, and various CGM indices were compared among low (≤0.16), medium (0.60) GGap tertile groups. Results: In the high GGap group, the average blood glucose was lower, while the Time Below Range ) and ), and low blood glucose index (LBGI) were higher than in the low and middle GGap groups. Patients with minimum blood glucose levels of ≥ 4%, and TBR ≥ 1% had significantly higher GGap values. Conclusion: This is the first study to show the strong association of high GGap with CGM‐based hypoglycemic indices in T2DM. To achieve diabetes treatment that effectively prevents the progression of diabetic complications, it is essential to assess the GGap of the individual patient before intensifying diabetes management.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0257
Renal function trajectories before and during the COVID-19 pandemic in Japanese individuals with type 1 diabetes: a post-hoc analysis of the multicenter retrospective investigation by the IPRA-CKD study group
The coronavirus disease 2019 (COVID-19) pandemic and associated lifestyle changes have affected metabolic status in individuals with diabetes. The impact of these changes on renal function in individuals with type 1 diabetes (T1D) remains unclear. We performed a post-hoc analysis of a multicenter retrospective cohort study (the IPRA-CKD study) including 190 Japanese individuals with T1D who were not receiving sodium–glucose cotransporter 2 inhibitors. Participants were recruited between June 2022 and July 2023, and longitudinal data over a consecutive 60-month period preceding enrollment were extracted at 6-month intervals and divided into periods before and during the pandemic. Annual rates of estimated glomerular filtration rate (eGFR) decline were compared between the periods before and during the COVID-19 pandemic using a linear mixed-effects model. The eGFR decline was not accelerated during the pandemic compared with before the pandemic; the estimated eGFR slopes were –1.54 ± 0.28 mL/min/1.73 m2/year before the pandemic and –1.05 ± 0.22 mL/min/1.73 m2/year during the pandemic (p = 0.27). Glycemic control was preserved during the pandemic, despite small but significant increases in body weight, blood pressure, and insulin dose. Exploratory subgroup analyses suggested a less steep eGFR decline during the pandemic among participants with body mass index ≥25 kg/m2 or those receiving renin–angiotensin system inhibitors; however, these findings should be interpreted as hypothesis-generating. In this multicenter cohort of individuals with T1D, the COVID-19 pandemic was not associated with accelerated eGFR decline overall.Clinical Trial Registry (CTR) registration: UMIN-CTR000047441
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- p. EJ26-0257
Open AccessRenal function trajectories before and during the COVID-19 pandemic in Japanese individuals with type 1 diabetes: a post-hoc analysis of the multicenter retrospective investigation by the IPRA-CKD study group
The coronavirus disease 2019 (COVID-19) pandemic and associated lifestyle changes have affected metabolic status in individuals with diabetes. The impact of these changes on renal function in individuals with type 1 diabetes (T1D) remains unclear. We performed a post-hoc analysis of a multicenter retrospective cohort study (the IPRA-CKD study) including 190 Japanese individuals with T1D who were not receiving sodium–glucose cotransporter 2 inhibitors. Participants were recruited between June 2022 and July 2023, and longitudinal data over a consecutive 60-month period preceding enrollment were extracted at 6-month intervals and divided into periods before and during the pandemic. Annual rates of estimated glomerular filtration rate (eGFR) decline were compared between the periods before and during the COVID-19 pandemic using a linear mixed-effects model. The eGFR decline was not accelerated during the pandemic compared with before the pandemic; the estimated eGFR slopes were –1.54 ± 0.28 mL/min/1.73 m2/year before the pandemic and –1.05 ± 0.22 mL/min/1.73 m2/year during the pandemic (p = 0.27). Glycemic control was preserved during the pandemic, despite small but significant increases in body weight, blood pressure, and insulin dose. Exploratory subgroup analyses suggested a less steep eGFR decline during the pandemic among participants with body mass index ≥25 kg/m2 or those receiving renin–angiotensin system inhibitors; however, these findings should be interpreted as hypothesis-generating. In this multicenter cohort of individuals with T1D, the COVID-19 pandemic was not associated with accelerated eGFR decline overall.Clinical Trial Registry (CTR) registration: UMIN-CTR000047441
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e4671246
Association of the Fibrosis‐4 Index With Indices of Atherosclerosis in Patients With Type 2 Diabetes: An Exploratory Subanalysis of a Prospective Observational Cohort Study
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by insulin resistance and metabolic syndrome, with type 2 diabetes mellitus (T2DM) as a major risk factor. Additionally, MASLD has been linked to liver fibrosis, which is associated with increased cardiovascular risk. Although noninvasive liver fibrosis markers are widely used, the association of these markers with atherosclerosis and continuous glucose monitoring (CGM) indices in T2DM remains unclear. We aimed to investigate the associations of the fibrosis‐4 (FIB‐4) index with atherosclerosis and CGM indices in patients with T2DM. Methods: This study was an exploratory subanalysis of a prospective observational cohort. Among 999 outpatients with T2DM who underwent baseline CGM, 887 patients (excluding heavy alcohol consumers) were analyzed. FIB‐4, a noninvasive marker of liver fibrosis, was calculated. Associations of FIB‐4 with carotid ultrasound, vascular wave velocity tests, and CGM indices were explored. Results: After adjusting for disease duration, body mass index (BMI), glycated hemoglobin (HbA1c), gamma‐glutamyl transferase, and complications, FIB‐4 severity category showed significant associations with mean intima‐media thickness (IMT), common carotid artery (CCA) maximum IMT, and brachial–ankle pulse wave velocity in ordinal logistic analyses. Consistent with the ordinal logistic analyses, FIB‐4 was independently associated with mean IMT in multivariable linear regression. Among the CGM indices, FIB‐4 was positively associated with both mean glucose and the standard deviation (SD) of mean glucose. Moreover, FIB‐4 was negatively associated with time in range (TIR) and positively with time above range (TAR). Conclusions: In Japanese patients with T2DM, FIB‐4 is associated with carotid thickening and arterial stiffness. Moreover, FIB‐4 correlates with the duration of hyperglycemia, suggesting that liver fibrosis may be linked to atherosclerosis through mechanisms involving poor glycemic control. Assessment of liver fibrosis in T2DM is imperative, necessitating monitoring of atherosclerosis and cardiovascular diseases (CVDs) in cases of suspected advanced liver fibrosis. Trial Registration: The study has been registered (UMIN000032325) in the University Hospital Medical Information Network Clinical Trials Registry, a nonprofit organization in Japan that meets the requirements of the International Committee of Medical Journal Editors.
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e4671246
Open AccessAssociation of the Fibrosis‐4 Index With Indices of Atherosclerosis in Patients With Type 2 Diabetes: An Exploratory Subanalysis of a Prospective Observational Cohort Study
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is characterized by insulin resistance and metabolic syndrome, with type 2 diabetes mellitus (T2DM) as a major risk factor. Additionally, MASLD has been linked to liver fibrosis, which is associated with increased cardiovascular risk. Although noninvasive liver fibrosis markers are widely used, the association of these markers with atherosclerosis and continuous glucose monitoring (CGM) indices in T2DM remains unclear. We aimed to investigate the associations of the fibrosis‐4 (FIB‐4) index with atherosclerosis and CGM indices in patients with T2DM. Methods: This study was an exploratory subanalysis of a prospective observational cohort. Among 999 outpatients with T2DM who underwent baseline CGM, 887 patients (excluding heavy alcohol consumers) were analyzed. FIB‐4, a noninvasive marker of liver fibrosis, was calculated. Associations of FIB‐4 with carotid ultrasound, vascular wave velocity tests, and CGM indices were explored. Results: After adjusting for disease duration, body mass index (BMI), glycated hemoglobin (HbA1c), gamma‐glutamyl transferase, and complications, FIB‐4 severity category showed significant associations with mean intima‐media thickness (IMT), common carotid artery (CCA) maximum IMT, and brachial–ankle pulse wave velocity in ordinal logistic analyses. Consistent with the ordinal logistic analyses, FIB‐4 was independently associated with mean IMT in multivariable linear regression. Among the CGM indices, FIB‐4 was positively associated with both mean glucose and the standard deviation (SD) of mean glucose. Moreover, FIB‐4 was negatively associated with time in range (TIR) and positively with time above range (TAR). Conclusions: In Japanese patients with T2DM, FIB‐4 is associated with carotid thickening and arterial stiffness. Moreover, FIB‐4 correlates with the duration of hyperglycemia, suggesting that liver fibrosis may be linked to atherosclerosis through mechanisms involving poor glycemic control. Assessment of liver fibrosis in T2DM is imperative, necessitating monitoring of atherosclerosis and cardiovascular diseases (CVDs) in cases of suspected advanced liver fibrosis. Trial Registration: The study has been registered (UMIN000032325) in the University Hospital Medical Information Network Clinical Trials Registry, a nonprofit organization in Japan that meets the requirements of the International Committee of Medical Journal Editors.
- Open Access
- 9 October 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (12) , 2160-2172
Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open‐label clinical trial ( RESOLUTION study)
Introduction: The renoprotective effects of luseogliflozin, a sodium‐glucose cotransporter 2 inhibitor, in patients with renal dysfunction are unexamined. We evaluated the efficacy of luseogliflozin in slowing renal function decline among patients with type 2 diabetes mellitus and moderate to severe renal dysfunction. Materials and Methods: In a multicenter, randomized, open‐label, controlled clinical trial, patients with type 2 diabetes mellitus and an estimated glomerular filtration rate based on serum creatinine (eGFRcreat) of 15–45 mL/min/1.73 m 2 were randomized into luseogliflozin or control groups. The primary endpoint was the change in eGFRcreat from baseline to 104 weeks. Secondary endpoints included eGFRcreat and eGFRcreat slope changes from 4 to 104 weeks (chronic eGFRcreat slope). Results: Among 152 participants, eGFRcreat change from baseline to 104 weeks did not significantly differ between groups. The luseogliflozin group showed a significant decrease in eGFRcreat from 2 to 12 weeks compared to the control group; the largest decline occurred at 4 weeks (initial eGFR decline). There were no differences between groups thereafter. The chronic eGFRcreat slope was less negative in the luseogliflozin group compared to the control group (not significant). Conversely, subgroup analysis indicated that the difference in chronic eGFRcreat slope between groups was significantly greater (with a less negative or even positive slope observed in the luseogliflozin group compared to the control group) among patients with eGFRcreat 2 , urinary albumin/creatinine ratio l useogliflozin may provide renoprotective benefits in patients with type 2 diabetes mellitus and moderate‐to‐severe renal impairment, potentially by slowing eGFRcreat decline post‐initial decline.
- 9 October 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (12) , 2160-2172
Open AccessEfficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open‐label clinical trial ( RESOLUTION study)
Introduction: The renoprotective effects of luseogliflozin, a sodium‐glucose cotransporter 2 inhibitor, in patients with renal dysfunction are unexamined. We evaluated the efficacy of luseogliflozin in slowing renal function decline among patients with type 2 diabetes mellitus and moderate to severe renal dysfunction. Materials and Methods: In a multicenter, randomized, open‐label, controlled clinical trial, patients with type 2 diabetes mellitus and an estimated glomerular filtration rate based on serum creatinine (eGFRcreat) of 15–45 mL/min/1.73 m 2 were randomized into luseogliflozin or control groups. The primary endpoint was the change in eGFRcreat from baseline to 104 weeks. Secondary endpoints included eGFRcreat and eGFRcreat slope changes from 4 to 104 weeks (chronic eGFRcreat slope). Results: Among 152 participants, eGFRcreat change from baseline to 104 weeks did not significantly differ between groups. The luseogliflozin group showed a significant decrease in eGFRcreat from 2 to 12 weeks compared to the control group; the largest decline occurred at 4 weeks (initial eGFR decline). There were no differences between groups thereafter. The chronic eGFRcreat slope was less negative in the luseogliflozin group compared to the control group (not significant). Conversely, subgroup analysis indicated that the difference in chronic eGFRcreat slope between groups was significantly greater (with a less negative or even positive slope observed in the luseogliflozin group compared to the control group) among patients with eGFRcreat 2 , urinary albumin/creatinine ratio l useogliflozin may provide renoprotective benefits in patients with type 2 diabetes mellitus and moderate‐to‐severe renal impairment, potentially by slowing eGFRcreat decline post‐initial decline.
- Open Access
- 6 March 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (3) , e70065
Association of Glycaemia Risk Index With Indices of Atherosclerosis: A Cross‐Sectional Study
Aims: This study determined the association of the glycaemia risk index (GRI), a novel comprehensive metric derived from continuous glucose monitoring (CGM), and atherosclerosis in patients with type 2 diabetes (T2DM).Methods: We evaluated the relationship between GRI and intima‐media thickness (IMT), gray‐scale median (GSM), tissue characteristics of the carotid artery wall, and brachial‐ankle pulse wave velocity (baPWV), using baseline data from a multicenter prospective cohort study of 1000 Japanese patients with T2DM free of cardiovascular disease (CVD).Results: The study subjects were 999 patients (age: 64.6 ± 9.6 years, mean ± SD, 60.9% males, body mass index: 24.6 ± 3.9 kg/m2, HbA1c 7.1% ± 0.8%, TIR 78.9% ± 18.6%) with T2DM (duration of 12.9 ± 8.5 years). A higher GRI was associated with a longer duration of diabetes, a higher HbA1c level, a mean glucose level, and baPWV, and lower mean GSM. No association was noted between GRI and mean IMT. GRI was significantly associated with mean GSM (regression coefficient, β = −0.1277; 95% confidence interval: CI: −0.2165 to −0.0390, p = 0.005) and baPWV (regression coefficient, β = −3.1568; 95% CI: 1.5058 to 4.8079, p < 0.001) after adjustment for various cardiovascular risk factors.Conclusions: GRI is a potentially useful predictor of atherosclerosis in patients with T2DM. Our findings suggest that GRI, a marker of the risk of hypoglycaemia and hyperglycaemia, may serve as a clinically useful tool for the assessment of the risk of CVD in patients with T2DM, independent of the classical cardiovascular risk factors.
- 6 March 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (3) , e70065
Open AccessAssociation of Glycaemia Risk Index With Indices of Atherosclerosis: A Cross‐Sectional Study
Aims: This study determined the association of the glycaemia risk index (GRI), a novel comprehensive metric derived from continuous glucose monitoring (CGM), and atherosclerosis in patients with type 2 diabetes (T2DM).Methods: We evaluated the relationship between GRI and intima‐media thickness (IMT), gray‐scale median (GSM), tissue characteristics of the carotid artery wall, and brachial‐ankle pulse wave velocity (baPWV), using baseline data from a multicenter prospective cohort study of 1000 Japanese patients with T2DM free of cardiovascular disease (CVD).Results: The study subjects were 999 patients (age: 64.6 ± 9.6 years, mean ± SD, 60.9% males, body mass index: 24.6 ± 3.9 kg/m2, HbA1c 7.1% ± 0.8%, TIR 78.9% ± 18.6%) with T2DM (duration of 12.9 ± 8.5 years). A higher GRI was associated with a longer duration of diabetes, a higher HbA1c level, a mean glucose level, and baPWV, and lower mean GSM. No association was noted between GRI and mean IMT. GRI was significantly associated with mean GSM (regression coefficient, β = −0.1277; 95% confidence interval: CI: −0.2165 to −0.0390, p = 0.005) and baPWV (regression coefficient, β = −3.1568; 95% CI: 1.5058 to 4.8079, p < 0.001) after adjustment for various cardiovascular risk factors.Conclusions: GRI is a potentially useful predictor of atherosclerosis in patients with T2DM. Our findings suggest that GRI, a marker of the risk of hypoglycaemia and hyperglycaemia, may serve as a clinically useful tool for the assessment of the risk of CVD in patients with T2DM, independent of the classical cardiovascular risk factors.
- Open Access
- 1 January 2025
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 72 (11) , 1197-1204
Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism
Patients with primary hyperparathyroidism (PHPT) ineligible for surgery require medical management for hypercalcemia and osteoporosis. The aim of this retrospective study was to determine the long-term effects of evocalcet on serum corrected calcium (cCa) levels and bone mineral density (BMD) in PHPT. The study included 26 patients with PHPT and hypercalcemia treated with evocalcet (7 switched from cinacalcet) for at least 24 months. Their mean age was 75.5 years. At baseline, cCa, phosphorus, and median intact parathyroid hormone levels were 10.76 mg/dL, 2.91 mg/dL, and 99.0 pg/mL, respectively. Osteoporosis was observed in 18 (69%), and 16 (62%) patients were on treatment for osteoporosis. Twenty-four months of evocalcet treatment significantly decreased cCa level to 9.77 mg/dL (mean change: -0.98 ± 0.91 mg/dL). Patients who switched from cinacalcet had a smaller reduction in cCa levels (-0.31 ± 0.72 mg/dL) than did those who were evocalcet-naïve (-1.23 ± 0.87 mg/dL, p = 0.019). By 24 months, 84.6% of patients had achieved a cCa level ≤10.3 mg/dL. Multivariate analysis identified baseline calcium levels as determinants of calcium level changes at 24 months. For patients not receiving osteoporosis treatment, lumbar spine BMD remained largely unchanged, whereas femoral neck BMD showed a decreasing trend. No other serious side effects requiring dose-lowering or withdrawal were noted. Evocalcet maintained its calcium-lowering effect for over 24 months in patients with PHPT, suggesting its potential as a medical treatment for surgery-ineligible patients. Careful monitoring of BMD is necessary during long-term evocalcet treatment to prevent worsening of osteoporosis.
- 1 January 2025
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 72 (11) , 1197-1204
Open AccessEffectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism
Patients with primary hyperparathyroidism (PHPT) ineligible for surgery require medical management for hypercalcemia and osteoporosis. The aim of this retrospective study was to determine the long-term effects of evocalcet on serum corrected calcium (cCa) levels and bone mineral density (BMD) in PHPT. The study included 26 patients with PHPT and hypercalcemia treated with evocalcet (7 switched from cinacalcet) for at least 24 months. Their mean age was 75.5 years. At baseline, cCa, phosphorus, and median intact parathyroid hormone levels were 10.76 mg/dL, 2.91 mg/dL, and 99.0 pg/mL, respectively. Osteoporosis was observed in 18 (69%), and 16 (62%) patients were on treatment for osteoporosis. Twenty-four months of evocalcet treatment significantly decreased cCa level to 9.77 mg/dL (mean change: -0.98 ± 0.91 mg/dL). Patients who switched from cinacalcet had a smaller reduction in cCa levels (-0.31 ± 0.72 mg/dL) than did those who were evocalcet-naïve (-1.23 ± 0.87 mg/dL, p = 0.019). By 24 months, 84.6% of patients had achieved a cCa level ≤10.3 mg/dL. Multivariate analysis identified baseline calcium levels as determinants of calcium level changes at 24 months. For patients not receiving osteoporosis treatment, lumbar spine BMD remained largely unchanged, whereas femoral neck BMD showed a decreasing trend. No other serious side effects requiring dose-lowering or withdrawal were noted. Evocalcet maintained its calcium-lowering effect for over 24 months in patients with PHPT, suggesting its potential as a medical treatment for surgery-ineligible patients. Careful monitoring of BMD is necessary during long-term evocalcet treatment to prevent worsening of osteoporosis.
- Open Access
- 27 December 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (4) , 449-458
Comparative effects of fixed‐dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial
Introduction: The aim of this study was to compare the effects of mitiglinide/voglibose with those of glimepiride on glycemic variability and vascular endothelial function in patients with type 2 diabetes.Materials and Methods: It was a multicenter, open‐label, randomized, crossover study. Hospitalized patients received either mitiglinide/voglibose (three times daily administration of 10 mg mitiglinide and 0.2 mg voglibose) or glimepiride (once‐daily 2 mg) in random order, each for 5 days. The reactive hyperemia index (RHI) and the mean amplitude of glycemic excursions (MAGE) were measured as co‐primary endpoints using reactive hyperemia peripheral arterial tonometry and continuous glucose monitoring.Results: The analysis included 30 patients (15 in each group). The RHI was 1.670 ± 0.369 during treatment with mitiglinide/voglibose and 1.716 ± 0.492 during treatment with glimepiride, with no significant difference between the two. MAGE was significantly lower in the mitiglinide/voglibose group (47.6 ± 18.5 mg/dL) than in the glimepiride group (100.6 ± 32.2 mg/dL). Although the mean blood glucose levels over the entire 24 h period were comparable between the two groups, the use of mitiglinide/voglibose was associated with a lower standard deviation of mean glucose, coefficient of variation, and mean postprandial glucose excursion compared with glimepiride. The time below range (180, >200, and 250 mg/dL) were lower in the mitiglinide/voglibose group, while the time in range (70–180 mg/dL) was higher.Conclusions: In our short‐duration randomized crossover study, although not impacting vascular endothelial function, mitiglinide/voglibose demonstrated potential benefits in reducing glycemic variability, postprandial hyperglycemia, and hypoglycemia in patients with type 2 diabetes.
- 27 December 2023
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (4) , 449-458
Open AccessComparative effects of fixed‐dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial
Introduction: The aim of this study was to compare the effects of mitiglinide/voglibose with those of glimepiride on glycemic variability and vascular endothelial function in patients with type 2 diabetes.Materials and Methods: It was a multicenter, open‐label, randomized, crossover study. Hospitalized patients received either mitiglinide/voglibose (three times daily administration of 10 mg mitiglinide and 0.2 mg voglibose) or glimepiride (once‐daily 2 mg) in random order, each for 5 days. The reactive hyperemia index (RHI) and the mean amplitude of glycemic excursions (MAGE) were measured as co‐primary endpoints using reactive hyperemia peripheral arterial tonometry and continuous glucose monitoring.Results: The analysis included 30 patients (15 in each group). The RHI was 1.670 ± 0.369 during treatment with mitiglinide/voglibose and 1.716 ± 0.492 during treatment with glimepiride, with no significant difference between the two. MAGE was significantly lower in the mitiglinide/voglibose group (47.6 ± 18.5 mg/dL) than in the glimepiride group (100.6 ± 32.2 mg/dL). Although the mean blood glucose levels over the entire 24 h period were comparable between the two groups, the use of mitiglinide/voglibose was associated with a lower standard deviation of mean glucose, coefficient of variation, and mean postprandial glucose excursion compared with glimepiride. The time below range (180, >200, and 250 mg/dL) were lower in the mitiglinide/voglibose group, while the time in range (70–180 mg/dL) was higher.Conclusions: In our short‐duration randomized crossover study, although not impacting vascular endothelial function, mitiglinide/voglibose demonstrated potential benefits in reducing glycemic variability, postprandial hyperglycemia, and hypoglycemia in patients with type 2 diabetes.
- Open Access
- 2 August 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Effect of skin–capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease
The effect of the skin–capsular distance (SCD) on the controlled attenuation parameter (CAP) for diagnosis of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) remains unclear. The SCD was measured using B-mode ultrasound, and the CAP was measured using the M probe of FibroScan®. According to the indications of the M probe, 113 patients with an SCD of ≤ 25 mm were included in the present study. The association between the SCD and CAP was investigated, and the diagnostic performance of the SCD-adjusted CAP was tested. The SCD showed the most significant positive correlation with the CAP (ρ = 0.329, p < 0.001). In the multiple regression analysis, the SCD and serum albumin concentration were associated with the CAP, independent of pathological liver steatosis. According to the multivariate analysis, two different formulas were developed to obtain the adjusted CAP using the SCD and serum albumin concentration as follows: adjusted CAP (dB/m) = CAP − (5.26 × SCD) and adjusted CAP (dB/m) = CAP − (5.35 × SCD) − (25.77 × serum albumin concentration). The area under the receiver operating characteristic curve for diagnosis of a steatosis score ≥ 2 of adjusted CAP was 0.678 and 0.684 respectively, which were significantly greater than the original CAP (0.621: p = 0.030 and p = 0.024). The SCD is associated with the CAP independent of liver steatosis. Adjustment of the CAP using the SCD improves the diagnostic performance of the CAP in NAFLD.
- 2 August 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Open AccessEffect of skin–capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease
The effect of the skin–capsular distance (SCD) on the controlled attenuation parameter (CAP) for diagnosis of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) remains unclear. The SCD was measured using B-mode ultrasound, and the CAP was measured using the M probe of FibroScan®. According to the indications of the M probe, 113 patients with an SCD of ≤ 25 mm were included in the present study. The association between the SCD and CAP was investigated, and the diagnostic performance of the SCD-adjusted CAP was tested. The SCD showed the most significant positive correlation with the CAP (ρ = 0.329, p < 0.001). In the multiple regression analysis, the SCD and serum albumin concentration were associated with the CAP, independent of pathological liver steatosis. According to the multivariate analysis, two different formulas were developed to obtain the adjusted CAP using the SCD and serum albumin concentration as follows: adjusted CAP (dB/m) = CAP − (5.26 × SCD) and adjusted CAP (dB/m) = CAP − (5.35 × SCD) − (25.77 × serum albumin concentration). The area under the receiver operating characteristic curve for diagnosis of a steatosis score ≥ 2 of adjusted CAP was 0.678 and 0.684 respectively, which were significantly greater than the original CAP (0.621: p = 0.030 and p = 0.024). The SCD is associated with the CAP independent of liver steatosis. Adjustment of the CAP using the SCD improves the diagnostic performance of the CAP in NAFLD.
- Open Access
- 23 July 2020
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 12 (4) , 601-609
Associations between urinary 6‐sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes
Aims/Introduction: There are limited reports on the association between melatonin levels and vascular complications in patients with type 2 diabetes. The aim of this study was to determine the association between urinary 6‐sulfatoxymelatonin, which is a urinary metabolite of melatonin, and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes.Materials and Methods: This retrospective study included patients (167 patients with type 2 diabetes and 27 patients without diabetes adjusted for age and sex) admitted to the hospital who underwent measurement of urinary 6‐sulfatoxymelatonin. The urinary 6‐sulfatoxymelatonin/creatinine ratio (6‐SMT) was calculated.Results: The natural logarithmically scaled 6‐SMT level (Ln 6‐SMT) was significantly lower in type 2 diabetes patients (1.9 ± 1.1) compared with patients without diabetes (2.8 ± 1.0, P < 0.001). Multivariate linear regression analysis identified duration of diabetes, smoking status, urinary albumin‐to‐creatinine ratio, retinopathy and coronary heart disease as factors that could influence Ln 6‐SMT levels in type 2 diabetes patients (R2 = 0.232, P < 0.001). Ln 6‐SMT was associated with decreased odds of diabetic retinopathy, even after adjustment for various confounding factors (odds ratio 0.559, 95% confidence interval 0.369–0.846, P = 0.006). Similarly, Ln 6‐SMT was associated with decreased odds of coronary heart disease (odds ratio 0.442, P = 0.030).Conclusions: Our results showed the presence of low levels of Ln 6‐SMT in type 2 diabetes patients relative to patients without diabetes. Furthermore, Ln 6‐SMT is an independent risk factor of diabetic retinopathy and coronary heart diseases. These findings suggest that 6‐SMT could be a useful biomarker for the prediction of micro‐ and macrovasculopathies in patients with type 2 diabetes.
- 23 July 2020
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 12 (4) , 601-609
Open AccessAssociations between urinary 6‐sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes
Aims/Introduction: There are limited reports on the association between melatonin levels and vascular complications in patients with type 2 diabetes. The aim of this study was to determine the association between urinary 6‐sulfatoxymelatonin, which is a urinary metabolite of melatonin, and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes.Materials and Methods: This retrospective study included patients (167 patients with type 2 diabetes and 27 patients without diabetes adjusted for age and sex) admitted to the hospital who underwent measurement of urinary 6‐sulfatoxymelatonin. The urinary 6‐sulfatoxymelatonin/creatinine ratio (6‐SMT) was calculated.Results: The natural logarithmically scaled 6‐SMT level (Ln 6‐SMT) was significantly lower in type 2 diabetes patients (1.9 ± 1.1) compared with patients without diabetes (2.8 ± 1.0, P < 0.001). Multivariate linear regression analysis identified duration of diabetes, smoking status, urinary albumin‐to‐creatinine ratio, retinopathy and coronary heart disease as factors that could influence Ln 6‐SMT levels in type 2 diabetes patients (R2 = 0.232, P < 0.001). Ln 6‐SMT was associated with decreased odds of diabetic retinopathy, even after adjustment for various confounding factors (odds ratio 0.559, 95% confidence interval 0.369–0.846, P = 0.006). Similarly, Ln 6‐SMT was associated with decreased odds of coronary heart disease (odds ratio 0.442, P = 0.030).Conclusions: Our results showed the presence of low levels of Ln 6‐SMT in type 2 diabetes patients relative to patients without diabetes. Furthermore, Ln 6‐SMT is an independent risk factor of diabetic retinopathy and coronary heart diseases. These findings suggest that 6‐SMT could be a useful biomarker for the prediction of micro‐ and macrovasculopathies in patients with type 2 diabetes.
- Open Access
- 18 June 2020
- Published by Springer Nature in Research Square
Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Type 2 Diabetes: A Retrospective Study
Background: The aim of this study was to determine the association between serum 25-hydroxyvitamin D (25(OH)D) levels and vascular endothelial function in patients with type 2 diabetes (T2D).Methods: This retrospective study included 113 T2D patients who were admitted for in-hospital diabetes educational program and underwent measurements of serum 25(OH)D levels and reactive hyperemia index (RHI). The primary endpoint was the association between serum 25(OH)D levels and RHI in T2D patients.Results: Serum 25(OH)D levels correlated significantly with RHI in T2D patients (r=0.285, p=0.002). Receiver operating characteristic (ROC) curve analysis showed that serum 25(OH)D level of 16.5 ng/mL is the optimal cut-off level for predicting vascular endothelial dysfunction (RHIConclusions: The results demonstrated the association of serum 25(OH)D levels with endothelial function in T2D patients and identified serum 25(OH)D level of <16.5 ng/mL as a predictor of vascular endothelial dysfunction. Serum 25(OH)D level is a potentially useful marker of vascular endothelial dysfunction in T2D patients.
- 18 June 2020
- Published by Springer Nature in Research Square
Open AccessLow Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Type 2 Diabetes: A Retrospective Study
Background: The aim of this study was to determine the association between serum 25-hydroxyvitamin D (25(OH)D) levels and vascular endothelial function in patients with type 2 diabetes (T2D).Methods: This retrospective study included 113 T2D patients who were admitted for in-hospital diabetes educational program and underwent measurements of serum 25(OH)D levels and reactive hyperemia index (RHI). The primary endpoint was the association between serum 25(OH)D levels and RHI in T2D patients.Results: Serum 25(OH)D levels correlated significantly with RHI in T2D patients (r=0.285, p=0.002). Receiver operating characteristic (ROC) curve analysis showed that serum 25(OH)D level of 16.5 ng/mL is the optimal cut-off level for predicting vascular endothelial dysfunction (RHIConclusions: The results demonstrated the association of serum 25(OH)D levels with endothelial function in T2D patients and identified serum 25(OH)D level of <16.5 ng/mL as a predictor of vascular endothelial dysfunction. Serum 25(OH)D level is a potentially useful marker of vascular endothelial dysfunction in T2D patients.